235 related articles for article (PubMed ID: 24121274)
21. Hepatocyte growth factor activator inhibitor type 2 (HAI-2) modulates hepcidin expression by inhibiting the cell surface protease matriptase-2.
Maurer E; Gütschow M; Stirnberg M
Biochem J; 2013 Mar; 450(3):583-93. PubMed ID: 23293962
[TBL] [Abstract][Full Text] [Related]
22. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo.
Oberst M; Anders J; Xie B; Singh B; Ossandon M; Johnson M; Dickson RB; Lin CY
Am J Pathol; 2001 Apr; 158(4):1301-11. PubMed ID: 11290548
[TBL] [Abstract][Full Text] [Related]
23. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Betsunoh H; Mukai S; Akiyama Y; Fukushima T; Minamiguchi N; Hasui Y; Osada Y; Kataoka H
Cancer Sci; 2007 Apr; 98(4):491-8. PubMed ID: 17309599
[TBL] [Abstract][Full Text] [Related]
24. Androgen-Induced TMPRSS2 Activates Matriptase and Promotes Extracellular Matrix Degradation, Prostate Cancer Cell Invasion, Tumor Growth, and Metastasis.
Ko CJ; Huang CC; Lin HY; Juan CP; Lan SW; Shyu HY; Wu SR; Hsiao PW; Huang HP; Shun CT; Lee MS
Cancer Res; 2015 Jul; 75(14):2949-60. PubMed ID: 26018085
[TBL] [Abstract][Full Text] [Related]
25. Reduced prostasin (CAP1/PRSS8) activity eliminates HAI-1 and HAI-2 deficiency-associated developmental defects by preventing matriptase activation.
Szabo R; Uzzun Sales K; Kosa P; Shylo NA; Godiksen S; Hansen KK; Friis S; Gutkind JS; Vogel LK; Hummler E; Camerer E; Bugge TH
PLoS Genet; 2012; 8(8):e1002937. PubMed ID: 22952456
[TBL] [Abstract][Full Text] [Related]
26. Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.
Chou FP; Chen YW; Zhao XF; Xu-Monette ZY; Young KH; Gartenhaus RB; Wang JK; Kataoka H; Zuo AH; Barndt RJ; Johnson M; Lin CY
Am J Pathol; 2013 Oct; 183(4):1306-17. PubMed ID: 24070417
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells.
Tsui KH; Chang PL; Feng TH; Chung LC; Hsu SY; Juang HH
Anticancer Res; 2008; 28(4A):1977-83. PubMed ID: 18649735
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis.
Tsui KH; Chang PL; Feng TH; Chung LC; Sung HC; Juang HH
Anticancer Res; 2008; 28(4A):1993-9. PubMed ID: 18649738
[TBL] [Abstract][Full Text] [Related]
29. HAI-2 stabilizes, inhibits and regulates SEA-cleavage-dependent secretory transport of matriptase.
Nonboe AW; Krigslund O; Soendergaard C; Skovbjerg S; Friis S; Andersen MN; Ellis V; Kawaguchi M; Kataoka H; Bugge TH; Vogel LK
Traffic; 2017 Jun; 18(6):378-391. PubMed ID: 28371047
[TBL] [Abstract][Full Text] [Related]
30. Loss of the matriptase inhibitor HAI-2 during prostate cancer progression.
Bergum C; List K
Prostate; 2010 Sep; 70(13):1422-8. PubMed ID: 20687215
[TBL] [Abstract][Full Text] [Related]
31. Roles of functional and structural domains of hepatocyte growth factor activator inhibitor type 1 in the inhibition of matriptase.
Kojima K; Tsuzuki S; Fushiki T; Inouye K
J Biol Chem; 2008 Feb; 283(5):2478-87. PubMed ID: 18048349
[TBL] [Abstract][Full Text] [Related]
32. Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.
Najy AJ; Dyson G; Jena BP; Lin CY; Kim HR
Am J Physiol Cell Physiol; 2016 Feb; 310(4):C293-304. PubMed ID: 26157007
[TBL] [Abstract][Full Text] [Related]
33. Cleavage of hepatocyte growth factor activator inhibitor-1 by membrane-type MMP-1 activates matriptase.
Domoto T; Takino T; Guo L; Sato H
Cancer Sci; 2012 Mar; 103(3):448-54. PubMed ID: 22118498
[TBL] [Abstract][Full Text] [Related]
34. HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease.
Oberst MD; Chen LY; Kiyomiya K; Williams CA; Lee MS; Johnson MD; Dickson RB; Lin CY
Am J Physiol Cell Physiol; 2005 Aug; 289(2):C462-70. PubMed ID: 15800053
[TBL] [Abstract][Full Text] [Related]
35. Crystal structures of matriptase in complex with its inhibitor hepatocyte growth factor activator inhibitor-1.
Zhao B; Yuan C; Li R; Qu D; Huang M; Ngo JC
J Biol Chem; 2013 Apr; 288(16):11155-64. PubMed ID: 23443661
[TBL] [Abstract][Full Text] [Related]
36. Hepatocyte growth factor activator inhibitor-1 has a complex subcellular itinerary.
Godiksen S; Selzer-Plon J; Pedersen ED; Abell K; Rasmussen HB; Szabo R; Bugge TH; Vogel LK
Biochem J; 2008 Jul; 413(2):251-9. PubMed ID: 18402552
[TBL] [Abstract][Full Text] [Related]
37. Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development.
Szabo R; Molinolo A; List K; Bugge TH
Oncogene; 2007 Mar; 26(11):1546-56. PubMed ID: 16983341
[TBL] [Abstract][Full Text] [Related]
38. Regulation of pericellular proteolysis by hepatocyte growth factor activator inhibitor type 1 (HAI-1) in trophoblast cells.
Kohama K; Kawaguchi M; Fukushima T; Lin CY; Kataoka H
Hum Cell; 2012 Dec; 25(4):100-10. PubMed ID: 23248048
[TBL] [Abstract][Full Text] [Related]
39. Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase.
Lee CF; Dang A; Hernandez E; Pong RC; Chen B; Sonavane R; Raj G; Kapur P; Lin HY; Wu SR; Ko CJ; Lo UG; Lee HY; Hsieh JT; Lee MS
Oncogene; 2019 Jul; 38(28):5580-5598. PubMed ID: 31152147
[TBL] [Abstract][Full Text] [Related]
40. Insufficiency of hepatocyte growth factor activator inhibitor-1 confers lymphatic invasion of tongue carcinoma cells.
Izumi A; Yamamoto K; Kawaguchi M; Yamashita F; Fukushima T; Kiwaki T; Tanaka H; Yamashita Y; Kataoka H
Cancer Sci; 2022 Jun; 113(6):2179-2193. PubMed ID: 35332604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
